Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook

Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-ch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic advances in neurological disorders Jg. 18; S. 17562864251372752
Hauptverfasser: Klotz, Luisa, Berger, Thomas, Brownlee, Wallace J., Chan, Andrew, Lycke, Jan, Oreja-Guevara, Celia, Palavra, Filipe, Sacca, Francesco, Sejbaek, Tobias, Weber, Martin S., Giovannoni, Gavin
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England SAGE Publishing 01.01.2025
Schlagworte:
multiple sclerosis
natalizumab
Neurosciences
Neurovetenskaper
treatment strategies
treatment strategies
multiple sclerosis
natalizumab
ISSN:1756-2864, 1756-2856, 1756-2864
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20 years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.
AbstractList Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.
Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20 years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.
Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20 years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20 years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.
Author Klotz, Luisa
Weber, Martin S.
Chan, Andrew
Sacca, Francesco
Giovannoni, Gavin
Lycke, Jan
Sejbaek, Tobias
Oreja-Guevara, Celia
Palavra, Filipe
Berger, Thomas
Brownlee, Wallace J.
Author_xml – sequence: 1
  givenname: Luisa
  orcidid: 0000-0001-5439-9633
  surname: Klotz
  fullname: Klotz, Luisa
  organization: Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Münster 48149, Germany
– sequence: 2
  givenname: Thomas
  orcidid: 0000-0001-5626-1144
  surname: Berger
  fullname: Berger, Thomas
  organization: Department of Neurology, Medical University of Vienna, Vienna, Austria, Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria
– sequence: 3
  givenname: Wallace J.
  surname: Brownlee
  fullname: Brownlee, Wallace J.
  organization: National Hospital for Neurology and Neurosurgery, London, UK
– sequence: 4
  givenname: Andrew
  surname: Chan
  fullname: Chan, Andrew
  organization: Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
– sequence: 5
  givenname: Jan
  orcidid: 0000-0002-7891-8466
  surname: Lycke
  fullname: Lycke, Jan
  organization: Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
– sequence: 6
  givenname: Celia
  orcidid: 0000-0002-9221-5716
  surname: Oreja-Guevara
  fullname: Oreja-Guevara, Celia
  organization: Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
– sequence: 7
  givenname: Filipe
  orcidid: 0000-0002-2165-130X
  surname: Palavra
  fullname: Palavra, Filipe
  organization: Centre for Child Development, Neuropediatric Unit, Hospital Pediátrico, Unidade Local de Saúde de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
– sequence: 8
  givenname: Francesco
  surname: Sacca
  fullname: Sacca, Francesco
  organization: GENESIS Department, Federico II University, Naples, Italy
– sequence: 9
  givenname: Tobias
  surname: Sejbaek
  fullname: Sejbaek, Tobias
  organization: Department of Neurology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark
– sequence: 10
  givenname: Martin S.
  surname: Weber
  fullname: Weber, Martin S.
  organization: Department of Neurology, Institute of Neuropathology, University Medical Center, Göttingen, Germany, Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany
– sequence: 11
  givenname: Gavin
  surname: Giovannoni
  fullname: Giovannoni, Gavin
  organization: Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40969774$$D View this record in MEDLINE/PubMed
https://gup.ub.gu.se/publication/355711$$DView record from Swedish Publication Index (Göteborgs universitet)
BookMark eNplkU1vFSEUhompsR_6A9wYlm6m8s3gzjRqmzRx064JMHAzlYERhjTXXy_XWxuNq0PePHkOOe85OEk5eQDeYnSJsZQfsOSCjIIRjqkkkpMX4OyQDYfw5K_3KTiv9QEhQSRDr8ApQ0ooKdkZuL979Gnbw703pcIcYDKbifPPthgL5wSXFrd5jR5WF33Jda4fYfS15lT7NCX5CZo0wdC2VjzMbYs5f38NXgYTq3_zNC_A_ZfPd1fXw-23rzdXn24HxxDZhnEckQuSUDwhyqUgjCs7eSNUoDQQp6SagsJSBGVGhlig1igXiHKCYYIZvQA3R--UzYNey7yYstfZzPp3kMtOm7LN_eu68wQjwWWwpC-3ViJmicKCMo6ddd01HF310a_N_mPbtVX3aNd09ZpyLjHu_Psjv5b8o_m66WWuzsdoks-tako4IUT0pR1994Q2u_jpWf2nhg7gI-D6iWvx4RnBSB-q1v9VTX8BMY-ZkQ
Cites_doi 10.3389/fneur.2018.00031
10.1007/s00415-016-8340-8
10.1007/s11940-021-00677-1
10.1212/NXI.0000000000000961
10.1158/1078-0432.CCR-11-2904
10.1177/17562864231221331
10.1016/S1474-4422(20)30067-3
10.1007/s13311-021-01102-w
10.1111/ane.12250
10.1007/s00415-023-11955-0
10.1016/j.ebiom.2021.103581
10.1016/j.msard.2024.105852
10.1016/B978-0-323-98817-9.00016-8
10.3389/fneur.2015.00018
10.1001/jamaneurol.2019.2670
10.1001/jamanetworkopen.2024.6345
10.1016/j.msard.2017.07.003
10.1212/NXI.0000000000000574
10.1186/s12879-020-05475-9
10.1016/j.msard.2022.103995
10.1002/ana.21163
10.1016/j.jns.2020.116827
10.1016/S1047-9651(18)30254-7
10.1016/S1474-4422(17)30282-X
10.1016/S1474-4422(09)70021-3
10.1016/j.lpm.2021.104069
10.1212/NXI.0000000000200303
10.1056/NEJMoa044396
10.1016/S1474-4422(19)30391-6
10.1111/joim.13215
10.1186/1477-7525-10-155
10.1016/j.jns.2023.120689
10.1111/ene.13536
10.1056/NEJMoa020732
10.1016/j.cell.2023.03.008
10.1002/acn3.51495
10.1007/s00415-015-7986-y
10.1371/journal.pone.0170395
10.1007/s00415-012-6414-9
10.1212/WNL.0000000000008243
10.1007/s10072-024-07930-w
10.1177/13524585241267211
10.3389/fimmu.2023.1326651
10.3389/fimmu.2023.1197195
10.1136/jnnp-2019-322326
10.1007/s00415-021-10950-7
10.2147/tcrm.2007.3.2.259
10.1038/s41572-018-0041-4
10.1212/01.WNL.0000128136.79044.D6
10.1177/1352458520926869
10.1016/j.msard.2023.104561
10.1007/s40120-024-00633-6
10.1111/ajco.13375
10.1212/WNL.0b013e31828c2fa1
10.1136/practneurol-2015-001355
10.1007/s00415-015-7666-y
10.1002/ana.22247
10.1016/j.msard.2024.105605
10.1177/13524585211003020
10.1126/scitranslmed.adg7863
10.1056/NEJMoa0706383
10.1177/13524585211044479
10.1177/1352458520969145
10.1177/17562864241241382
10.1177/1352458511399611
10.1586/14737175.4.4.571
10.1080/14740338.2017.1346082
10.1007/s10875-011-9522-x
10.1016/j.msard.2022.104477
10.1007/s10072-021-05127-z
10.1007/s00415-024-12256-w
10.1155/2018/1924174
10.1007/s11910-018-0857-z
10.1016/j.jns.2021.117385
10.1046/j.1365-2567.1997.00351.x
10.1186/s12883-018-1026-3
10.1007/s11011-017-0169-z
10.1093/brain/awac016
10.3389/fimmu.2023.1242508
10.2165/00023210-200519110-00002
10.1016/j.msard.2024.105594
10.1007/s00415-017-8594-9
10.1016/j.msard.2024.105543
10.1097/MD.0000000000037297
10.3389/fneur.2022.824926
10.1056/NEJMoa1917246
10.1097/NAN.0000000000000519
10.1136/jnnp-2022-330467
10.1001/jamaneurol.2021.2738
10.1212/WNL.0000000000000541
10.1016/j.medj.2023.05.001
10.1016/j.msard.2016.10.002
10.3389/fneur.2022.1016377
10.1016/S1474-4422(22)00040-0
10.1038/s41577-021-00547-6
10.3389/fimmu.2021.715195
10.1038/s41582-020-00427-y
10.1136/jnnp-2023-332804
10.1056/NEJMoa044397
10.2217/nmt-2023-0047
10.1016/j.msard.2021.102865
10.1177/1352458511428082
10.1136/bmjopen-2020-038861
10.1212/NXI.0000000000000726
10.1212/WNL.0000000000004485
10.1212/WNL.0000000000010380
10.1016/j.msard.2025.106285
10.1007/s00415-012-6809-7
10.1001/jamaneurol.2020.1568
10.1016/j.ejpn.2012.09.004
10.1177/13524585211000280
10.1016/j.msard.2023.104713
10.1007/s40263-022-00950-0
10.1001/archneurol.2008.505
10.1007/s40259-024-00671-4
10.1177/13524585221108080
10.1016/j.msard.2021.102842
10.2217/nmt-2021-0058
10.3390/jpm12010119
10.1242/jcs.111.9.1165
10.1007/s13311-022-01202-1
10.1007/s13311-021-01037-2
10.1007/s00415-023-11686-2
10.1002/acn3.50883
10.1002/jcph.707
10.3390/ctn8030026
10.1056/NEJMoa1606468
10.1186/s12883-015-0433-y
10.1016/S1474-4422(18)30040-1
10.1016/j.neurot.2024.e00338
10.1016/j.clineuro.2024.108378
10.1016/j.msard.2013.02.006
10.2147/DNND.S138835
10.1212/WNL.53.3.466
10.1007/s00415-004-0332-4
10.1016/j.jns.2017.10.008
10.1177/1756285610381526
10.1016/j.msard.2024.105796
10.1101/cshperspect.a028928
10.1016/S1474-4422(10)70028-4
10.1007/s13311-022-01224-9
10.1177/13524585211006372
ContentType Journal Article
Copyright The Author(s), 2025.
Copyright_xml – notice: The Author(s), 2025.
DBID AAYXX
CITATION
NPM
7X8
ADTPV
AOWAS
F1U
DOA
DOI 10.1177/17562864251372752
DatabaseName CrossRef
PubMed
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-2864
ExternalDocumentID oai_doaj_org_article_121210657fb2402bb704b29163451cbc
oai_gup_ub_gu_se_355711
40969774
10_1177_17562864251372752
Genre Journal Article
Review
GroupedDBID ---
-TM
01A
0R~
123
18M
29Q
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AAYXX
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABNCE
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACHEB
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFFHD
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
CITATION
COF
CS3
DC-
DC.
DIK
DOPDO
E3Z
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
PSYQQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AASGM
NPM
PUEGO
7X8
ADTPV
AOWAS
F1U
ID FETCH-LOGICAL-c402t-8880cf7231d035762459bdea69f33f2c979df9176f9a8404f3ba9cf29c6412143
IEDL.DBID DOA
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001572922100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1756-2864
1756-2856
IngestDate Tue Oct 14 19:00:23 EDT 2025
Thu Nov 27 03:11:43 EST 2025
Fri Sep 19 21:01:07 EDT 2025
Mon Sep 22 02:45:04 EDT 2025
Sat Nov 29 07:29:46 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords treatment strategies
multiple sclerosis
natalizumab
Language English
License The Author(s), 2025.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c402t-8880cf7231d035762459bdea69f33f2c979df9176f9a8404f3ba9cf29c6412143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5439-9633
0000-0001-5626-1144
0000-0002-2165-130X
0000-0002-9221-5716
0000-0002-7891-8466
OpenAccessLink https://doaj.org/article/121210657fb2402bb704b29163451cbc
PMID 40969774
PQID 3252226210
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_121210657fb2402bb704b29163451cbc
swepub_primary_oai_gup_ub_gu_se_355711
proquest_miscellaneous_3252226210
pubmed_primary_40969774
crossref_primary_10_1177_17562864251372752
PublicationCentury 2000
PublicationDate 2025-01-01
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Therapeutic advances in neurological disorders
PublicationTitleAlternate Ther Adv Neurol Disord
PublicationYear 2025
Publisher SAGE Publishing
Publisher_xml – name: SAGE Publishing
References e_1_3_4_3_2
e_1_3_4_152_2
e_1_3_4_110_2
e_1_3_4_133_2
e_1_3_4_156_2
e_1_3_4_114_2
e_1_3_4_61_2
e_1_3_4_84_2
e_1_3_4_7_2
e_1_3_4_118_2
e_1_3_4_80_2
e_1_3_4_23_2
e_1_3_4_69_2
e_1_3_4_42_2
e_1_3_4_27_2
e_1_3_4_65_2
e_1_3_4_46_2
e_1_3_4_88_2
e_1_3_4_163_2
e_1_3_4_140_2
e_1_3_4_121_2
e_1_3_4_102_2
e_1_3_4_144_2
e_1_3_4_72_2
Zhu C (e_1_3_4_123_2) 2022; 93
e_1_3_4_125_2
Oreja-Guevara C (e_1_3_4_137_2) 2023; 15
Nelson SML (e_1_3_4_154_2) 2018; 8
e_1_3_4_95_2
e_1_3_4_106_2
e_1_3_4_148_2
e_1_3_4_30_2
e_1_3_4_129_2
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_57_2
e_1_3_4_53_2
e_1_3_4_15_2
e_1_3_4_38_2
e_1_3_4_76_2
e_1_3_4_99_2
e_1_3_4_19_2
e_1_3_4_2_2
Li E (e_1_3_4_13_2) 2024; 30
e_1_3_4_151_2
e_1_3_4_132_2
e_1_3_4_113_2
e_1_3_4_155_2
e_1_3_4_62_2
e_1_3_4_85_2
e_1_3_4_117_2
e_1_3_4_159_2
e_1_3_4_6_2
e_1_3_4_81_2
Perncezky J (e_1_3_4_100_2) 2022; 14
e_1_3_4_20_2
e_1_3_4_43_2
e_1_3_4_24_2
e_1_3_4_47_2
e_1_3_4_66_2
e_1_3_4_89_2
e_1_3_4_28_2
e_1_3_4_120_2
e_1_3_4_162_2
e_1_3_4_101_2
e_1_3_4_124_2
e_1_3_4_143_2
e_1_3_4_73_2
e_1_3_4_96_2
e_1_3_4_105_2
e_1_3_4_128_2
e_1_3_4_147_2
e_1_3_4_50_2
e_1_3_4_92_2
e_1_3_4_109_2
e_1_3_4_12_2
e_1_3_4_58_2
e_1_3_4_54_2
e_1_3_4_31_2
e_1_3_4_16_2
e_1_3_4_77_2
e_1_3_4_39_2
e_1_3_4_131_2
e_1_3_4_150_2
e_1_3_4_112_2
e_1_3_4_135_2
e_1_3_4_82_2
e_1_3_4_9_2
e_1_3_4_116_2
e_1_3_4_139_2
e_1_3_4_158_2
e_1_3_4_63_2
e_1_3_4_40_2
e_1_3_4_5_2
e_1_3_4_44_2
e_1_3_4_21_2
e_1_3_4_48_2
e_1_3_4_86_2
e_1_3_4_25_2
e_1_3_4_67_2
e_1_3_4_29_2
e_1_3_4_142_2
e_1_3_4_161_2
e_1_3_4_146_2
e_1_3_4_165_2
e_1_3_4_93_2
e_1_3_4_104_2
e_1_3_4_74_2
Vivekanandan G (e_1_3_4_91_2) 2021; 13
e_1_3_4_127_2
e_1_3_4_51_2
e_1_3_4_108_2
e_1_3_4_70_2
e_1_3_4_55_2
e_1_3_4_32_2
e_1_3_4_59_2
e_1_3_4_97_2
e_1_3_4_36_2
e_1_3_4_78_2
e_1_3_4_17_2
e_1_3_4_153_2
e_1_3_4_130_2
e_1_3_4_111_2
e_1_3_4_157_2
e_1_3_4_134_2
e_1_3_4_60_2
e_1_3_4_83_2
Landi D (e_1_3_4_136_2) 2022; 93
e_1_3_4_115_2
e_1_3_4_138_2
e_1_3_4_41_2
e_1_3_4_119_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_45_2
e_1_3_4_68_2
e_1_3_4_26_2
e_1_3_4_49_2
e_1_3_4_64_2
e_1_3_4_87_2
Planas R (e_1_3_4_8_2) 2014; 5
e_1_3_4_160_2
e_1_3_4_141_2
e_1_3_4_164_2
e_1_3_4_122_2
e_1_3_4_145_2
e_1_3_4_71_2
e_1_3_4_94_2
e_1_3_4_103_2
e_1_3_4_126_2
e_1_3_4_149_2
Stankiewicz JM (e_1_3_4_35_2) 2019; 7
e_1_3_4_52_2
e_1_3_4_90_2
e_1_3_4_107_2
e_1_3_4_79_2
e_1_3_4_33_2
e_1_3_4_10_2
e_1_3_4_75_2
e_1_3_4_98_2
e_1_3_4_37_2
e_1_3_4_14_2
e_1_3_4_56_2
e_1_3_4_18_2
References_xml – ident: e_1_3_4_19_2
  doi: 10.3389/fneur.2018.00031
– volume: 7
  year: 2019
  ident: e_1_3_4_35_2
  article-title: An argument for broad use of high efficacy treatments in early multiple sclerosis
  publication-title: Neurol Neuroimmunol Neuroinflamm
– ident: e_1_3_4_151_2
  doi: 10.1007/s00415-016-8340-8
– ident: e_1_3_4_40_2
  doi: 10.1007/s11940-021-00677-1
– volume: 5
  start-page: 25
  year: 2014
  ident: e_1_3_4_8_2
  article-title: Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
  publication-title: Patient Relat Outcome Meas
– ident: e_1_3_4_150_2
  doi: 10.1212/NXI.0000000000000961
– volume: 14
  year: 2022
  ident: e_1_3_4_100_2
  article-title: Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
  publication-title: J Cent Nerv Syst Dis
– ident: e_1_3_4_11_2
– ident: e_1_3_4_162_2
  doi: 10.1158/1078-0432.CCR-11-2904
– ident: e_1_3_4_41_2
  doi: 10.1177/17562864231221331
– ident: e_1_3_4_39_2
  doi: 10.1016/S1474-4422(20)30067-3
– ident: e_1_3_4_108_2
  doi: 10.1007/s13311-021-01102-w
– ident: e_1_3_4_107_2
  doi: 10.1111/ane.12250
– ident: e_1_3_4_25_2
– ident: e_1_3_4_118_2
  doi: 10.1007/s00415-023-11955-0
– ident: e_1_3_4_128_2
  doi: 10.1016/j.ebiom.2021.103581
– ident: e_1_3_4_114_2
  doi: 10.1016/j.msard.2024.105852
– ident: e_1_3_4_17_2
  doi: 10.1016/B978-0-323-98817-9.00016-8
– ident: e_1_3_4_78_2
  doi: 10.3389/fneur.2015.00018
– ident: e_1_3_4_44_2
– ident: e_1_3_4_9_2
  doi: 10.1001/jamaneurol.2019.2670
– ident: e_1_3_4_124_2
  doi: 10.1001/jamanetworkopen.2024.6345
– ident: e_1_3_4_158_2
  doi: 10.1016/j.msard.2017.07.003
– ident: e_1_3_4_51_2
  doi: 10.1212/NXI.0000000000000574
– ident: e_1_3_4_132_2
  doi: 10.1186/s12879-020-05475-9
– ident: e_1_3_4_56_2
  doi: 10.1016/j.msard.2022.103995
– ident: e_1_3_4_75_2
  doi: 10.1002/ana.21163
– ident: e_1_3_4_29_2
  doi: 10.1016/j.jns.2020.116827
– ident: e_1_3_4_20_2
  doi: 10.1016/S1047-9651(18)30254-7
– ident: e_1_3_4_98_2
  doi: 10.1016/S1474-4422(17)30282-X
– ident: e_1_3_4_30_2
  doi: 10.1016/S1474-4422(09)70021-3
– ident: e_1_3_4_141_2
  doi: 10.1016/j.lpm.2021.104069
– ident: e_1_3_4_147_2
  doi: 10.1212/NXI.0000000000200303
– ident: e_1_3_4_55_2
  doi: 10.1056/NEJMoa044396
– ident: e_1_3_4_66_2
  doi: 10.1016/S1474-4422(19)30391-6
– ident: e_1_3_4_34_2
  doi: 10.1111/joim.13215
– ident: e_1_3_4_77_2
  doi: 10.1186/1477-7525-10-155
– ident: e_1_3_4_99_2
– volume: 13
  year: 2021
  ident: e_1_3_4_91_2
  article-title: Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review
  publication-title: Cureus
– ident: e_1_3_4_103_2
  doi: 10.1016/j.jns.2023.120689
– ident: e_1_3_4_4_2
  doi: 10.1111/ene.13536
– ident: e_1_3_4_153_2
  doi: 10.1056/NEJMoa020732
– ident: e_1_3_4_2_2
– ident: e_1_3_4_16_2
  doi: 10.1016/j.cell.2023.03.008
– ident: e_1_3_4_152_2
  doi: 10.1002/acn3.51495
– ident: e_1_3_4_37_2
  doi: 10.1007/s00415-015-7986-y
– ident: e_1_3_4_87_2
  doi: 10.1371/journal.pone.0170395
– ident: e_1_3_4_6_2
  doi: 10.1007/s00415-012-6414-9
– volume: 8
  year: 2018
  ident: e_1_3_4_154_2
  article-title: Natalizumab for induction of remission in Crohn’s disease
  publication-title: Cochrane Database Syst Rev
– ident: e_1_3_4_101_2
  doi: 10.1212/WNL.0000000000008243
– ident: e_1_3_4_53_2
  doi: 10.1007/s10072-024-07930-w
– ident: e_1_3_4_82_2
  doi: 10.1177/13524585241267211
– ident: e_1_3_4_165_2
  doi: 10.3389/fimmu.2023.1326651
– ident: e_1_3_4_149_2
  doi: 10.3389/fimmu.2023.1197195
– ident: e_1_3_4_5_2
  doi: 10.1136/jnnp-2019-322326
– ident: e_1_3_4_110_2
  doi: 10.1007/s00415-021-10950-7
– ident: e_1_3_4_14_2
  doi: 10.2147/tcrm.2007.3.2.259
– ident: e_1_3_4_15_2
  doi: 10.1038/s41572-018-0041-4
– ident: e_1_3_4_57_2
  doi: 10.1212/01.WNL.0000128136.79044.D6
– ident: e_1_3_4_70_2
  doi: 10.1177/1352458520926869
– volume: 15
  year: 2023
  ident: e_1_3_4_137_2
  article-title: Family planning in fertile-age patients with multiple sclerosis (MS) (ConPlanEM Study): Delphi consensus statements
  publication-title: Cureus
– ident: e_1_3_4_104_2
  doi: 10.1016/j.msard.2023.104561
– ident: e_1_3_4_45_2
– ident: e_1_3_4_143_2
  doi: 10.1007/s40120-024-00633-6
– ident: e_1_3_4_163_2
  doi: 10.1111/ajco.13375
– ident: e_1_3_4_93_2
  doi: 10.1212/WNL.0b013e31828c2fa1
– ident: e_1_3_4_42_2
  doi: 10.1136/practneurol-2015-001355
– ident: e_1_3_4_157_2
  doi: 10.1007/s00415-015-7666-y
– ident: e_1_3_4_73_2
  doi: 10.1002/ana.22247
– ident: e_1_3_4_109_2
  doi: 10.1016/j.msard.2024.105605
– ident: e_1_3_4_10_2
– ident: e_1_3_4_112_2
  doi: 10.1177/13524585211003020
– volume: 93
  start-page: 1306
  year: 2022
  ident: e_1_3_4_136_2
  article-title: Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
  publication-title: J Neurol Neurosurg Psychiatry
– ident: e_1_3_4_159_2
  doi: 10.1126/scitranslmed.adg7863
– ident: e_1_3_4_64_2
  doi: 10.1056/NEJMoa0706383
– ident: e_1_3_4_63_2
  doi: 10.1177/13524585211044479
– ident: e_1_3_4_79_2
  doi: 10.1177/1352458520969145
– ident: e_1_3_4_111_2
  doi: 10.1177/17562864241241382
– ident: e_1_3_4_69_2
  doi: 10.1177/1352458511399611
– volume: 93
  start-page: 1330
  year: 2022
  ident: e_1_3_4_123_2
  article-title: Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
  publication-title: J Neurol Neurosurg Psychiatry
– ident: e_1_3_4_47_2
  doi: 10.1586/14737175.4.4.571
– ident: e_1_3_4_88_2
  doi: 10.1080/14740338.2017.1346082
– ident: e_1_3_4_52_2
  doi: 10.1007/s10875-011-9522-x
– ident: e_1_3_4_32_2
– ident: e_1_3_4_122_2
  doi: 10.1016/j.msard.2022.104477
– ident: e_1_3_4_80_2
  doi: 10.1007/s10072-021-05127-z
– ident: e_1_3_4_121_2
  doi: 10.1007/s00415-024-12256-w
– ident: e_1_3_4_18_2
  doi: 10.1155/2018/1924174
– ident: e_1_3_4_22_2
  doi: 10.1007/s11910-018-0857-z
– ident: e_1_3_4_102_2
  doi: 10.1016/j.jns.2021.117385
– ident: e_1_3_4_50_2
  doi: 10.1046/j.1365-2567.1997.00351.x
– ident: e_1_3_4_24_2
  doi: 10.1186/s12883-018-1026-3
– ident: e_1_3_4_156_2
  doi: 10.1007/s11011-017-0169-z
– ident: e_1_3_4_28_2
  doi: 10.1093/brain/awac016
– ident: e_1_3_4_86_2
  doi: 10.3389/fimmu.2023.1242508
– ident: e_1_3_4_43_2
  doi: 10.2165/00023210-200519110-00002
– ident: e_1_3_4_119_2
  doi: 10.1016/j.msard.2024.105594
– ident: e_1_3_4_3_2
  doi: 10.1007/s00415-017-8594-9
– ident: e_1_3_4_95_2
– ident: e_1_3_4_120_2
  doi: 10.1016/j.msard.2024.105543
– ident: e_1_3_4_23_2
  doi: 10.1097/MD.0000000000037297
– volume: 30
  year: 2024
  ident: e_1_3_4_13_2
  article-title: Budget impact analysis of biosimilar natalizumab in the US
  publication-title: Am J Manag Care
– ident: e_1_3_4_7_2
  doi: 10.3389/fneur.2022.824926
– ident: e_1_3_4_62_2
  doi: 10.1056/NEJMoa1917246
– ident: e_1_3_4_139_2
  doi: 10.1097/NAN.0000000000000519
– ident: e_1_3_4_116_2
  doi: 10.1136/jnnp-2022-330467
– ident: e_1_3_4_33_2
– ident: e_1_3_4_38_2
  doi: 10.1001/jamaneurol.2021.2738
– ident: e_1_3_4_133_2
  doi: 10.1212/WNL.0000000000000541
– ident: e_1_3_4_125_2
  doi: 10.1016/j.medj.2023.05.001
– ident: e_1_3_4_83_2
  doi: 10.1016/j.msard.2016.10.002
– ident: e_1_3_4_161_2
  doi: 10.3389/fneur.2022.1016377
– ident: e_1_3_4_160_2
  doi: 10.1016/S1474-4422(22)00040-0
– ident: e_1_3_4_164_2
  doi: 10.1038/s41577-021-00547-6
– ident: e_1_3_4_140_2
  doi: 10.3389/fimmu.2021.715195
– ident: e_1_3_4_90_2
  doi: 10.1038/s41582-020-00427-y
– ident: e_1_3_4_135_2
  doi: 10.1136/jnnp-2023-332804
– ident: e_1_3_4_54_2
  doi: 10.1056/NEJMoa044397
– ident: e_1_3_4_60_2
  doi: 10.2217/nmt-2023-0047
– ident: e_1_3_4_146_2
  doi: 10.1016/j.msard.2021.102865
– ident: e_1_3_4_84_2
  doi: 10.1177/1352458511428082
– ident: e_1_3_4_59_2
  doi: 10.1136/bmjopen-2020-038861
– ident: e_1_3_4_130_2
  doi: 10.1212/NXI.0000000000000726
– ident: e_1_3_4_65_2
  doi: 10.1212/WNL.0000000000004485
– ident: e_1_3_4_127_2
  doi: 10.1212/WNL.0000000000010380
– ident: e_1_3_4_129_2
  doi: 10.1016/j.msard.2025.106285
– ident: e_1_3_4_58_2
  doi: 10.1007/s00415-012-6809-7
– ident: e_1_3_4_27_2
  doi: 10.1001/jamaneurol.2020.1568
– ident: e_1_3_4_144_2
  doi: 10.1016/j.ejpn.2012.09.004
– ident: e_1_3_4_68_2
  doi: 10.1177/13524585211000280
– ident: e_1_3_4_71_2
  doi: 10.1016/j.msard.2023.104713
– ident: e_1_3_4_76_2
  doi: 10.1007/s40263-022-00950-0
– ident: e_1_3_4_142_2
  doi: 10.1001/archneurol.2008.505
– ident: e_1_3_4_12_2
  doi: 10.1007/s40259-024-00671-4
– ident: e_1_3_4_105_2
  doi: 10.1177/13524585221108080
– ident: e_1_3_4_96_2
  doi: 10.1016/j.msard.2021.102842
– ident: e_1_3_4_31_2
  doi: 10.2217/nmt-2021-0058
– ident: e_1_3_4_94_2
– ident: e_1_3_4_36_2
  doi: 10.3390/jpm12010119
– ident: e_1_3_4_49_2
  doi: 10.1242/jcs.111.9.1165
– ident: e_1_3_4_81_2
  doi: 10.1007/s13311-022-01202-1
– ident: e_1_3_4_106_2
  doi: 10.1007/s13311-021-01037-2
– ident: e_1_3_4_67_2
  doi: 10.1007/s00415-023-11686-2
– ident: e_1_3_4_97_2
– ident: e_1_3_4_155_2
  doi: 10.1002/acn3.50883
– ident: e_1_3_4_113_2
  doi: 10.1002/jcph.707
– ident: e_1_3_4_138_2
  doi: 10.3390/ctn8030026
– ident: e_1_3_4_61_2
  doi: 10.1056/NEJMoa1606468
– ident: e_1_3_4_145_2
  doi: 10.1186/s12883-015-0433-y
– ident: e_1_3_4_89_2
  doi: 10.1016/S1474-4422(18)30040-1
– ident: e_1_3_4_117_2
  doi: 10.1016/j.neurot.2024.e00338
– ident: e_1_3_4_134_2
  doi: 10.1016/j.clineuro.2024.108378
– ident: e_1_3_4_85_2
  doi: 10.1016/j.msard.2013.02.006
– ident: e_1_3_4_21_2
  doi: 10.2147/DNND.S138835
– ident: e_1_3_4_48_2
  doi: 10.1212/WNL.53.3.466
– ident: e_1_3_4_72_2
  doi: 10.1007/s00415-004-0332-4
– ident: e_1_3_4_74_2
  doi: 10.1016/j.jns.2017.10.008
– ident: e_1_3_4_148_2
  doi: 10.1177/1756285610381526
– ident: e_1_3_4_115_2
  doi: 10.1016/j.msard.2024.105796
– ident: e_1_3_4_46_2
– ident: e_1_3_4_26_2
  doi: 10.1101/cshperspect.a028928
– ident: e_1_3_4_92_2
  doi: 10.1016/S1474-4422(10)70028-4
– ident: e_1_3_4_126_2
  doi: 10.1007/s13311-022-01224-9
– ident: e_1_3_4_131_2
  doi: 10.1177/13524585211006372
SSID ssj0062740
Score 2.3464518
SecondaryResourceType review_article
Snippet Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable...
SourceID doaj
swepub
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 17562864251372752
SubjectTerms multiple sclerosis
natalizumab
Neurosciences
Neurovetenskaper
treatment strategies
Title Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook
URI https://www.ncbi.nlm.nih.gov/pubmed/40969774
https://www.proquest.com/docview/3252226210
https://gup.ub.gu.se/publication/355711
https://doaj.org/article/121210657fb2402bb704b29163451cbc
Volume 18
WOSCitedRecordID wos001572922100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: DOA
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: 7X7
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: BENPR
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: PIMPY
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ZaxRBEC40iuRFvB2PpQXxQRicPqZ72zcjCQpmWSSB9anpMyzobMjsROKvt3qOYFTwxZeBaaaZor6ijqmerwBeYsRRGJltqQNlpagdLeehEmVCNxlStFb6HulParGYr1Z6-cuor3wmbKAHHhT3hrJMcSVrlVxuBDinKuEYJjVc1NQ7n71vpfRUTA0-OA-UmXqYmV4JY2T-BRPtk3IM2DW7EoV6sv6_ZZi_0Yf2IefgDtwec0XybpDxLlyLzT24dTh2w-_D8dF3DBkX5AKttSWbRJr8LWb9o_tmHVk3ZDosSFrcjnKs27fkK3o2NDTST4uIgdgmkIFXhOSzQZhyP4Djg_2j9x_KcUxC6VEh2xJr2MonhYlaqDiWD0zU2oVopU6cJ-a10iFhVSaTtljOicSd1T4x7aVA3Qr-EHaaTRMfA6EiCM-ictZVIkaESksfOPeyzrQudQGvJ7WZ04ENw9CRMPwPHRewlxV7-WAmsu4XEF4zwmv-BW8BLyZYDBp-7mbYJm661nCGqSOTuLuARwNel6_ColXmxLaAVwOAV4Q46U4NLp10po0G8y1F6ZP_IetT2GV5OnD_geYZ7GzPuvgcbvrz7bo9m8F1tVL9dT6DG3v7i-XnWW-0eLf8eLj88hMloutd
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twenty+years+of+natalizumab+in+multiple+sclerosis%3A+lessons+learned+and+future+outlook&rft.jtitle=Therapeutic+advances+in+neurological+disorders&rft.au=Klotz%2C+Luisa&rft.au=Berger%2C+Thomas&rft.au=Brownlee%2C+Wallace+J.&rft.au=Chan%2C+Andrew&rft.date=2025-01-01&rft.issn=1756-2864&rft.volume=18&rft_id=info:doi/10.1177%2F17562864251372752&rft.externalDocID=oai_gup_ub_gu_se_355711
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-2864&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-2864&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-2864&client=summon